PE20231555A1 - Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos - Google Patents
Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenosInfo
- Publication number
- PE20231555A1 PE20231555A1 PE2023001149A PE2023001149A PE20231555A1 PE 20231555 A1 PE20231555 A1 PE 20231555A1 PE 2023001149 A PE2023001149 A PE 2023001149A PE 2023001149 A PE2023001149 A PE 2023001149A PE 20231555 A1 PE20231555 A1 PE 20231555A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- crystalline
- estrogen receptor
- amorphous forms
- directed degradation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 1
- 230000034512 ubiquitination Effects 0.000 abstract 1
- 238000010798 ubiquitination Methods 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDO A UN POLIMORFO DEL COMPUESTO (S)-3-(5-(4-((1-(4-((1R,2S)-6-HIDROXI-2-FENIL-1,2,3,4-TETRAHIDRONAFTALEN-1-IL)FENIL)PIPERIDIN-4-IL)METIL)PIPERAZIN-1-IL)-1-OXOISOINDOLIN-2-IL)PIPERIDINA-2,6-DIONA (COMPUESTO A) QUE SE CARACTERIZA POR UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE INCLUYE PICOS A 13.9 °2THETA, 16.4 °2THETA Y 17.9 °2THETA MEDIANTE EL USO DE RADIACION DE CU K ALFA A UNA LONGITUD DE ONDA DE RAYOS X DE 1.5406 A. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE. DICHO COMPUESTO A ES UN MODULADOR UTIL DE LA UBIQUITINACION Y DEGRADACION DE PROTEINAS DIANA A TRAVES DE LA VIA UBIQUITINA-PROTEASOMA SIENDO UTIL EN EL TRATAMIENTO DEL CANCER DE MAMA O CANCER UTERINO O ENDOMETRIOSIS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078225P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050046 WO2022056368A1 (en) | 2020-09-14 | 2021-09-13 | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231555A1 true PE20231555A1 (es) | 2023-10-03 |
Family
ID=78080527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001149A PE20231555A1 (es) | 2020-09-14 | 2021-09-13 | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220081416A1 (es) |
| EP (1) | EP4211128A1 (es) |
| JP (1) | JP2023541434A (es) |
| KR (1) | KR20230069144A (es) |
| CN (1) | CN116390916A (es) |
| AR (1) | AR123492A1 (es) |
| AU (1) | AU2021342287A1 (es) |
| BR (1) | BR112023004656A2 (es) |
| CA (1) | CA3194954A1 (es) |
| CL (1) | CL2023000712A1 (es) |
| CO (1) | CO2023004435A2 (es) |
| CR (1) | CR20230162A (es) |
| DO (1) | DOP2023000052A (es) |
| EC (1) | ECSP23027481A (es) |
| IL (1) | IL301155A (es) |
| MX (1) | MX2023002979A (es) |
| PE (1) | PE20231555A1 (es) |
| RS (1) | RS20230288A1 (es) |
| TW (1) | TW202214236A (es) |
| WO (1) | WO2022056368A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3689868T1 (sl) * | 2016-12-01 | 2024-02-29 | Arvinas Operations, Inc. | Derivati tetrahidronaftalena in tetrahidroizokinolina kot razgrajevalci estrogenskih receptorjev |
-
2021
- 2021-09-13 IL IL301155A patent/IL301155A/en unknown
- 2021-09-13 EP EP21787193.8A patent/EP4211128A1/en active Pending
- 2021-09-13 RS RS20230288A patent/RS20230288A1/sr unknown
- 2021-09-13 CR CR20230162A patent/CR20230162A/es unknown
- 2021-09-13 MX MX2023002979A patent/MX2023002979A/es unknown
- 2021-09-13 US US17/472,847 patent/US20220081416A1/en active Pending
- 2021-09-13 PE PE2023001149A patent/PE20231555A1/es unknown
- 2021-09-13 WO PCT/US2021/050046 patent/WO2022056368A1/en active Application Filing
- 2021-09-13 BR BR112023004656A patent/BR112023004656A2/pt unknown
- 2021-09-13 TW TW110134024A patent/TW202214236A/zh unknown
- 2021-09-13 CN CN202180070126.4A patent/CN116390916A/zh active Pending
- 2021-09-13 AU AU2021342287A patent/AU2021342287A1/en active Pending
- 2021-09-13 CA CA3194954A patent/CA3194954A1/en active Pending
- 2021-09-13 KR KR1020237011950A patent/KR20230069144A/ko unknown
- 2021-09-13 AR ARP210102530A patent/AR123492A1/es unknown
- 2021-09-13 JP JP2023516491A patent/JP2023541434A/ja active Pending
-
2023
- 2023-03-13 CL CL2023000712A patent/CL2023000712A1/es unknown
- 2023-03-14 DO DO2023000052A patent/DOP2023000052A/es unknown
- 2023-04-10 CO CONC2023/0004435A patent/CO2023004435A2/es unknown
- 2023-04-14 EC ECSENADI202327481A patent/ECSP23027481A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023541434A (ja) | 2023-10-02 |
| RS20230288A1 (sr) | 2023-06-30 |
| TW202214236A (zh) | 2022-04-16 |
| MX2023002979A (es) | 2023-04-10 |
| BR112023004656A2 (pt) | 2023-05-09 |
| CA3194954A1 (en) | 2022-03-17 |
| AU2021342287A1 (en) | 2023-04-13 |
| IL301155A (en) | 2023-05-01 |
| WO2022056368A1 (en) | 2022-03-17 |
| DOP2023000052A (es) | 2023-07-31 |
| CO2023004435A2 (es) | 2023-04-27 |
| ECSP23027481A (es) | 2023-07-31 |
| CR20230162A (es) | 2023-06-02 |
| KR20230069144A (ko) | 2023-05-18 |
| EP4211128A1 (en) | 2023-07-19 |
| CN116390916A (zh) | 2023-07-04 |
| AR123492A1 (es) | 2022-12-07 |
| US20220081416A1 (en) | 2022-03-17 |
| CL2023000712A1 (es) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019009262A2 (es) | Derivados de oxadiazol microbicidas | |
| PE20231555A1 (es) | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos | |
| CL2018001859A1 (es) | Derivados de oxadiazol microbicidas. | |
| CO2018013594A2 (es) | Derivados de oxadiazol microbiocidas | |
| CR20190309A (es) | Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb | |
| CO2018003840A2 (es) | Derivados de oxadiazol microbicidas | |
| EP3724787A4 (en) | NON-VOLATILE MEMORY (NVM) ON CHIP | |
| AR055570A1 (es) | Polimorfo de oxazol - pirrolidina, procesos de obtencion y composiciones farmaceuticas. | |
| CR9664A (es) | Inhibidores de histona deacetilasa | |
| CL2008002159A1 (es) | Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad. | |
| BR112018070568A2 (pt) | derivados de oxadiazol microbiocidas | |
| CL2022003528A1 (es) | Formas cristalinas novedosas (divisional de cl 202002056). | |
| PE20120218A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
| CO2021015709A2 (es) | Compuestos herbicidas | |
| EA202091768A1 (ru) | Гербицидные комбинации | |
| SG11201806735QA (en) | Balance-hairspring oscillator for a timepiece | |
| UY38841A (es) | Composiciones para controlar parásitos | |
| AR059715A1 (es) | Variedades cristalinas de pesticidas derivados de 2-metil-4-trifluorometiltiazol-5-il | |
| ATE493707T1 (de) | Nichtflüchtiger speicher mit blockverwaltung | |
| BR112023003337A2 (pt) | Receptores de antígeno quimérico bcma | |
| FI20185939A1 (fi) | Menetelmä ja järjestely joustavan säiliön tyhjentämiseksi | |
| TR202004570U4 (tr) | Güneş taki̇bi̇ i̇çi̇n küresel mekani̇zma | |
| BR112022002457A2 (pt) | Poliolefina reciclada aprimorada | |
| UA45751S (uk) | 1.-6. опаковання для насіння | |
| ATE457642T1 (de) | Pflanzenschutzmittelzusammensetzung, die einen wirkstoff aus der reihe der azole und ein lösungsmittel enthält, sowie nützliche lösungsmittelzusammensetzung |